Please login to the form below
A Pharma Marketer's Guide to the Mobile Web
Despite an acknowledgement of the importance of mobile by the pharma sector, there has been little evidence to show that businesses are harnessing the mobile web effectively, instead opting for mobile app development. This guide sheds some light on mobile web opportunities for Pharma.
Find out what you could be doing to
develop your mobile presence effectively, by downloading A
Pharma Marketer's Guide to the Mobile Web, which was first published in November 2012.
High-level findings include:
- Patients’ needs for content are poorly served: only two European sites (both
concerned with contraception, from HRA and MSD UK) seem to recognise and
address patient audiences, though they serve these needs to widely differing
standards.
- Responsive design techniques for developing cross-device content are
under-represented: Astellas stands out strongly for its European corporate level
sites.
- Users with feature-phones are largely ignored: only Shire.com (providing
investor information) offers a mobile resource fully accessible and usable through
these devices.
- Mobile is (too often) an island: typically, mobile optimisation is reserved for a
single site in a company’s brand portfolio (the global, corporate.com) and when a
browsing journey leads to other properties (e.g. careers, investor or product – let
alone patient – info) the user is passed to a desktop site. It’s also an island where
the natives only speak English.
- Attention to detail is low across all sites: while homepages tend to look
attractive, our review highlights examples both of failure to implement W3C mobile
best practices (such as making all numbers click to call and providing links back
to a full site) and of flawed user acceptance testing which hasn’t detected broken
or missing links.
High-level findings include:
- Patients’ needs for content are poorly served: only two European sites (both
concerned with contraception, from HRA and MSD UK) seem to recognise and
address patient audiences, though they serve these needs to widely differing
standards.
- Responsive design techniques for developing cross-device content are
under-represented: Astellas stands out strongly for its European corporate level
sites.
- Users with feature-phones are largely ignored: only Shire.com (providing
investor information) offers a mobile resource fully accessible and usable through
these devices.
- Mobile is (too often) an island: typically, mobile optimisation is reserved for a
single site in a company’s brand portfolio (the global, corporate.com) and when a
browsing journey leads to other properties (e.g. careers, investor or product – let
alone patient – info) the user is passed to a desktop site. It’s also an island where
the natives only speak English.
- Attention to detail is low across all sites: while homepages tend to look
attractive, our review highlights examples both of failure to implement W3C mobile
best practices (such as making all numbers click to call and providing links back
to a full site) and of flawed user acceptance testing which hasn’t detected broken
or missing links.
Company Details
Blue Latitude Health
+44 203 328 1840
Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom
Latest content on this profile
- Three strategies for managing loss of exclusivity successfully
- Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
- What does the future hold for Medical Affairs?
- Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
- Unpacking rare diseases in the first edition of Delta magazine
- Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health
